Clinical features at the time of surgery, according to the type
| Feature . | Type of surgery . | P . | |
|---|---|---|---|
| Minor, n = 156 . | Major, n = 155 . | ||
| PV/ET, no./no. | 63/93 | 64/91 | .87 |
| Male/female, no./no. | 95/61 | 69/86 | .004* |
| Age at surgery, y; median (range) | 66 (21-87) | 56 (25-90) | .57 |
| Presence of at least 1 cardiovascular risk factor, no. (%)† | 77 (49.3) | 70 (45.2) | .45 |
| History of vascular disease, no. (%)‡ | 50 (32.1) | 50 (32.3) | .96 |
| Emergency procedure, no. (%) | 6 (3.8) | 19 (12.3) | .006* |
| General anesthesia, no. (%) | 49 (31.4) | 145 (92.9) | <.001* |
| Hemoglobin level, g/L, mean plus or minus SD | 141 ± 16 | 133 ± 18 | .001* |
| Hematocrit level, %, mean plus or minus SD | 42.7 ± 5.0 | 41.1 ± 5.2 | .004* |
| Leukocyte count, × 109/L, mean plus or minus SD | 8.1 ± 4.0 | 9.5 ± 5.1 | .007* |
| Platelet count, × 109/L, mean plus or minus SD | 494 ± 221 | 506 ± 231 | 0.64 |
| Type of prophylaxis at surgery, no. (%) | |||
| None | 64 (41.0) | 30 (19.3) | — |
| Antiplatelet | 32 (20.5) | 16 (10.3) | <.001* |
| Heparin lower dosage§ | 59 (37.8) | 30 (19.3) | — |
| Heparin higher dosage‖ | 1 (0.6) | 79 (50.9) | — |
| Chemotherapy or phlebotomy | 9 (5.7) | 17 (10.9) | .09 |
| Feature . | Type of surgery . | P . | |
|---|---|---|---|
| Minor, n = 156 . | Major, n = 155 . | ||
| PV/ET, no./no. | 63/93 | 64/91 | .87 |
| Male/female, no./no. | 95/61 | 69/86 | .004* |
| Age at surgery, y; median (range) | 66 (21-87) | 56 (25-90) | .57 |
| Presence of at least 1 cardiovascular risk factor, no. (%)† | 77 (49.3) | 70 (45.2) | .45 |
| History of vascular disease, no. (%)‡ | 50 (32.1) | 50 (32.3) | .96 |
| Emergency procedure, no. (%) | 6 (3.8) | 19 (12.3) | .006* |
| General anesthesia, no. (%) | 49 (31.4) | 145 (92.9) | <.001* |
| Hemoglobin level, g/L, mean plus or minus SD | 141 ± 16 | 133 ± 18 | .001* |
| Hematocrit level, %, mean plus or minus SD | 42.7 ± 5.0 | 41.1 ± 5.2 | .004* |
| Leukocyte count, × 109/L, mean plus or minus SD | 8.1 ± 4.0 | 9.5 ± 5.1 | .007* |
| Platelet count, × 109/L, mean plus or minus SD | 494 ± 221 | 506 ± 231 | 0.64 |
| Type of prophylaxis at surgery, no. (%) | |||
| None | 64 (41.0) | 30 (19.3) | — |
| Antiplatelet | 32 (20.5) | 16 (10.3) | <.001* |
| Heparin lower dosage§ | 59 (37.8) | 30 (19.3) | — |
| Heparin higher dosage‖ | 1 (0.6) | 79 (50.9) | — |
| Chemotherapy or phlebotomy | 9 (5.7) | 17 (10.9) | .09 |
indicates includes 1 patient treated with rituximals who obtained CR.
Diabetes on treatment, hypercholesterolemia on treatment, arterial hypertension on treatment, previous AT, cardiovascular diseases (atrial fibrillation, valvular or coronary disease), or smoking.
Defined as history of cardiovascular disease or venous thromboembolism before or after diagnosis.
Less than 3000 U anti-Xa/day for low-molecular-weight heparin or 5000 U twice daily or three times daily for unfractionated heparin (38 surgeries).
More than 3000 U anti-Xa/day for low-molecular-weight heparin.